Search | Applechat

Avinash Kumbharkar added blog Other
2026-07-29 13:51:20 -

Residual Disease Testing Market Growth Drivers, Regional Share, Competitive Landscape, and Forecast, 2026–2033
According to the latest report published by Data Bridge Market Research, the Minimal Residual Disease Market The minimal residual disease market size was valued at USD 2.13 billion in 2024 and is projected to reach USD 3.92 billion by 2032, with a CAGR of 7.90% during the forecast period of 2025 to 2032. All the data and information included in the global Minimal Residual...

0 Comments 0 Shares 68 Views 0 Reviews

Please log in to like, share and comment!
Avinash Kumbharkar added blog Other
2026-07-29 13:51:21 -

Residual Disease Testing Market Growth Drivers, Regional Share, Competitive Landscape, and Forecast, 2026–2033
According to the latest report published by Data Bridge Market Research, the Minimal Residual Disease Market The minimal residual disease market size was valued at USD 2.13 billion in 2024 and is projected to reach USD 3.92 billion by 2032, with a CAGR of 7.90% during the forecast period of 2025 to 2032. All the data and information included in the global Minimal Residual...

0 Comments 0 Shares 62 Views 0 Reviews

Please log in to like, share and comment!
Surbhi Verma added blog Health
2026-06-08 06:57:03 -

Single Cell Sequencing Market: How Is scDNA-Seq Transforming Minimal Residual Disease Monitoring?
Single-cell DNA sequencing for minimal residual disease (MRD) — the detection of residual malignant cells at 0.001% sensitivity following cancer therapy, enabling relapse prediction and treatment adaptation, representing 18% of clinical single-cell applications — creates the most commercially dynamic market segment, with the Single Cell Sequencing Market reflecting MRD monitoring as...

0 Comments 0 Shares 510 Views 0 Reviews

Please log in to like, share and comment!
Shital Sagare added blog Health
2026-01-21 01:26:00 -

Competitive Landscape and Future Projections
The competitive environment in the diagnostic space is characterized by aggressive R&D and strategic consolidation. Major players are acquiring smaller biotech firms to gain access to proprietary sequencing technologies and liquid biopsy platforms. Analysis of the Minimal Residual Disease Testing Market Share shows that a handful of companies hold a significant portion of the market,...

0 Comments 0 Shares 2K Views 0 Reviews

Please log in to like, share and comment!